The $1 Trillion Women's Health Gap

The $1 Trillion Women’s Health Gap, But Where Do Black Women Fit In?

There is a figure shaping global health conversations.

The World Economic Forum estimates that closing the women’s health gap could unlock up to $1 trillion in economic value. It is persuasive, widely quoted, and increasingly used to signal progress across policy and investment circles.

A more important question sits beneath that figure "where do Black women fit within this trillion-dollar future?"

The data tells a clear story once it is examined beyond headline numbers. Black women are consistently over represented in high-risk health outcomes while remaining under represented in research, funding allocation and clinical design. This is not a marginal issue. It is structural.

To understand the depth of this gap, it is necessary to move away from aggregate statistics and examine how it shows up across specific areas of women’s health. The pattern is not isolated to one condition or one stage of life. It repeats itself across fertility, chronic illness, pain management, and reproductive health.

Each example reveals the same underlying issue. The system captures disparity, yet struggles to design for it.

---

IVF:  Progress That Does Not Reach Everyone

IVF is often held up as a success story. It shows what can happen when science, policy and funding come together with intent. For many women, it has opened doors that once felt closed.

For Black women, those doors are not always as accessible.

In the United States, data linked to the Centre for Disease Control and Prevention shows that Black women experience higher rates of infertility, yet face lower access to fertility services, reduced referral rates, higher treatment costs and lower success outcomes.

Here is the uncomfortable truth. Black women face higher disparities in both access and outcomes across fertility treatment.

The science is advancing. If IVF is the “model, the model still excludes many women of colour. In the UK, data from the Human Fertilisation and Embryology Authority supports this finding as it shows lower success rates and reduced access to funded treatment for Black patients.

This is where the question becomes more human than clinical.

What does it mean to build a system that works in theory, but not in practice for everyone who needs it? We need to know where is the investment in culturally sensitive fertility support, early screening and equitable treatment pathways?

Menopause, Dementia and HRT: The Questions We Are Not Asking

It is well known in research that women are more likely to develop Alzheimer’s disease, particularly after menopause. What remains less understood is how this risk plays out across different racial groups.

In the United States, Black communities are more likely to experience dementia and less likely to receive early diagnosis. In the UK, Black women are significantly less likely to use HRT, often due to lack of access, information or trust in the system.

Research into hormone replacement therapy continues to produce mixed findings, yet large-scale studies rarely account for racial differences in menopausal symptoms, variations in hormone metabolism or the long-term effects of chronic stress linked to structural inequality.

Work by researchers such as Dr. Olajide Williams has emphasised that delayed diagnosis in Black communities is shaped by systemic bias rather than biological inevitability.

The National Institute for Health and Care Excellence shows that evidence on hormone replacement therapy and dementia is still evolving. Yet very few studies explore how menopause is experienced differently across cultures or how chronic stress, inequality and delayed diagnosis shape long-term outcomes for Black women.

What is clear is that Black women are not missing curiosity it is inclusion.

The limitation is clearly methodological because if research does not fully see you, it cannot design race‑specific solutions with accuracy?

Research that does not meaningfully include race cannot produce conclusions that apply universally.

Endometriosis: When Pain Is Not Believed

Endometriosis is often described through delay.

In the UK, diagnosis can take close to a decade. For many Black women, that timeline stretches even further.

The WEF report cites the UK’s growing awareness, policy support and employer initiatives to reduce endometriosis stigma but Black women continue to face:

• Longer diagnostic delays

• Symptoms dismissed as “period pain”

• Stereotypes that Black women are more “resilient” to pain

• Fewer referrals for specialist care

This is supported by reports such as 'Disbelieved, Dismissed, Delayed' which highlighted a pattern that feels deeply familiar. Symptoms are minimised. Pain is normalised. Women are told to wait.

In the United States, studies show that Black women are less likely to be diagnosed with endometriosis; not necessarily because they experience it less, but because they are less likely to be referred, investigated or believed. Unfortunately, symptoms are more likely to be dismissed as routine menstrual pain.

Stereotypes regarding higher pain tolerance persist despite being disproven. Referral pathways are slower and access to specialist care is more limited. Research from institutions such as Georgetown University has demonstrated that false beliefs about biological differences continue to influence clinical judgement.

The impact accumulates over time. Delayed diagnosis leads to chronic pain, which in turn affects productivity, income and long-term wellbeing. What begins as dismissal evolves into economic and social consequence.

Let's not make a mistake, there is a quiet cost to that disbelief. It shows up in in missed work, in strained relationships and in the slow erosion of trust in healthcare systems. A more difficult question remains largely unaddressed "who is measuring the full cost of ignoring the pain of Black women?"

Pain: The Difference Between Being Treated and Being Believed

Pain is one of the most human signals we have. It tells us something is wrong. It asks for attention.

Research across decades shows that Black patients and Black women in particular, are less likely to have that signal taken seriously.

In the United States, studies on maternal care show that Black women report higher levels of pain yet receive less adequate pain management.

In the UK, parliamentary reports and BBC investigations into maternity care have documented repeated accounts of Black women not being listened to during labour, even when complications were emerging.

This is not only about medicine. It is about trust. Yet new studies show biological differences in how women experience and recover from pain. But here is the deeper issue:

• Black women’s pain is systematically under treated

• They report being less believed in medical settings

• They receive less effective pain medication after childbirth, surgery and injury

When someone tells you they are in pain and the system hesitates to respond, the issue is no longer clinical. It is relational. So, where is the investment into intersectional pain research?

Heavy Menstrual Bleeding: When “Normal” Becomes Harmful

Heavy menstrual bleeding is often dismissed as something women simply have to manage. For many Black women, it is linked to fibroids, a condition that is more common, more severe and often develops earlier.

Globally, studies show that women of African descent experience higher prevalence and more aggressive forms of fibroids. In the United States, Black women are two to three times more likely to develop them. In the UK, the Royal College of Obstetricians and Gynaecologists has highlighted how Black women face longer delays in diagnosis and treatment.

What begins as “just heavy periods” can lead to anaemia, hospitalisation and in some cases, emergency intervention.

It is not just fibroids, heavy bleeding leads to anaemia, hospitalisations and blood transfusions costing nearly £5,000 per patient.

Least we forget, Black women are:

• Disproportionately affected by fibroids, a major cause of heavy bleeding

• More likely to be told to “wait it out”

• Less likely to be offered early treatment

• More likely to be admitted for emergency care rather than supported earlier in the community

The deeper issue is not the condition itself it is how long it is allowed to continue without being taken seriously.

The pattern is consistent. Normalisation delays action. Delay increases severity. Severity increases cost, both financial and personal. With greater technological advancements and data intelligence in the health service this leads to a critical question “why is early intervention not culturally tailored, especially in communities with the highest risk?”

Reproductive Health: The Most Visible Inequality

If there is one area where the gap is no longer subtle, it is reproductive health.

Across the UK, Black women are around four times more likely to die during pregnancy, childbirth or shortly after. This is not a new statistic. It has been repeated across national reviews, parliamentary inquiries and widely reported investigations. In the United States, the disparity remains between three to four times higher, with consistent data from the Centre for Disease Control and Prevention confirming significantly worse maternal outcomes for Black women.

What has shifted in recent years is not the data, but the visibility of the experience behind it.

BBC investigations, documentaries and work have brought forward testimonies from Black women and families that are difficult to watch and even harder to ignore. Women describing repeated attempts to seek help while in distress. Mothers explaining how their symptoms were minimised or dismissed. Families recounting the loss of loved ones where earlier intervention could have changed the outcome.

This is where the conversation moves beyond statistics.

The distress captured in those documentaries is not simply about individual cases. It reflects a pattern.

A pattern of delayed response, of not being listened to, of escalation only when conditions become critical. For many Black women watching, it is not just informative. It is recognisable.

That recognition carries its own weight.

It raises questions about trust, about safety and about whether the system will respond when it matters most. It also reinforces something that is often left unsaid in policy discussions. Access to healthcare does not guarantee equitable care within it.

Globally, the pattern holds. Data from the World Health Organisation shows that maternal mortality remains significantly higher in marginalised populations, driven not only by access, but by quality of care, timeliness of intervention and systemic inequality.

For women of African descent, whether in high-income countries or not, the risk profile remains consistently elevated.

Reproductive health exposes the system in its most critical moments.

These are not long-term conditions unfolding over years. These are acute, time-sensitive situations where clinical judgement, speed of response and the ability to listen can determine whether someone lives or dies.

The uncomfortable truth is this. The data exists. The stories have been told. The distress has been documented. What remains unresolved is whether the system is willing to respond with the urgency those stories demand.

What This Means in Practice

When you step back and look across these areas; fertility, menopause, dementia, endometriosis, pain management and reproductive health, the pattern is not fragmented. It is consistent.

Black women are more likely to experience higher disease burden, more likely to encounter delays in diagnosis and more likely to receive care that is reactive rather than preventative. The issue is not one condition failing. It is a system that responds late, unevenly and often without cultural or clinical precision.

What becomes clear is that this is not simply a healthcare issue. It is a design issue. Healthcare systems, research frameworks and funding models have not been built with the lived realities of Black women at the centre. They have been adapted around them and that difference matters. Adaptation reacts. Design anticipates.

Throughout the United States, the disparities are often most visible in prevalence and outcomes. Across the UK, they are more frequently seen in delayed access, longer waiting times and gaps in treatment pathways. Globally, the pattern holds steady.

Women of African descent experience earlier onset, more severe progression and poorer outcomes across multiple conditions. The consistency across regions removes any suggestion that this is incidental. It points to something structural.

The deeper implication is one that is often left unspoken. When Black women are not meaningfully included in clinical trials, research design or funding priorities, the resulting solutions are built on incomplete understanding. This does not only limit effectiveness. It risks reinforcing the very disparities those solutions are meant to address.

There is also a psychological and relational cost that sits alongside the clinical one.

Repeated experiences of being dismissed, not believed or having symptoms minimised erode trust in healthcare systems. Over time, that affects how and when women seek help, how they advocate for themselves and whether they engage with preventative care at all. What begins as a gap in treatment becomes a gap in trust.

This is why the $1 trillion conversation cannot be viewed purely through an economic lens. Investment without inclusion does not close gaps. It can, in fact, widen them.

The opportunity here is not only to invest more. It is to invest differently. That means designing research that reflects real populations, building pathways that account for cultural and structural realities and ensuring that early intervention is not a privilege, but a standard.

So the question is not abstract. It is immediate.

• Where are these gaps showing up in your experience of healthcare, whether personally or professionally?

• What has been dismissed, delayed or normalised that should have been taken seriously?

• Where do you see the biggest opportunity for change, in research, in policy or in frontline care?

• What would a system look like if it was designed with Black women at the centre?

Growth that does not account for disparity tends to benefit those already positioned to access it.

---

Like, comment and share your perspective. The more we surface what is lived, the harder it becomes to ignore.

---

If this is a conversation you want to be part of and you value articles that go beyond the surface and examine what is really happening, join the HealthTalk community.